Clinical Trial Update: Almonertinib Treats Advanced NSCLC Patients With EGFR Mutations Who Are Safety Intolerant After Osimertinib Treatment [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating almonertinib in advanced non-small cell lung cancer patients with EGFR mutations who are safety intolerant after osimertinib tre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Almonertinib (almonertinib)

Snippet

Sponsor: Shanghai Chest Hospital | Conditions: Lung Cancer, EGFR Gene Mutation | Phase 2 | Status: UNKNOWN